Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpe d'Huez Study: Linvoseltamab + Lenalidomide in NDMM Maintenance
NCT06910124Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of linvoseltamab in multiple myeloma (MM). Started Dec 2025; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06910124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910124.